Group 1 - The core viewpoint of the article indicates a recovery in the Chinese real estate sector, with notable stock price increases for several companies, including Greentown China, R&F Properties, New World Development, and Shimao Group [1] - According to CRIC, the top 100 real estate companies achieved a sales turnover of 253 billion yuan in October 2025, reflecting a month-on-month increase of 0.1% but a year-on-year decrease of 41.9% [1] - Cumulative performance shows that the top 100 real estate companies recorded a total sales turnover of 25,766.6 billion yuan, representing a year-on-year decline of 16%, with the decline rate widening by 4.2 percentage points compared to the first nine months of the year [1] Group 2 - Morgan Stanley suggests that the large number of second-hand homes on the market may continue to suppress market sentiment, exerting pressure on real estate sales and prices for the remainder of the year [1] - CITIC Securities reports an improvement in the supply and demand situation in the real estate market, indicating that adjustments have been sufficient, and forecasts a potential stabilization in the market by 2026 [1] - CITIC Securities believes that 2026 could be a critical year for real estate companies to repair their balance sheets, with some firms potentially reaching the bottom of their profit cycles, particularly those with good city layouts and valuable investment properties [1]

Group 1 - Hong Kong property stocks experienced a rise, with notable increases in several companies' stock prices [1] - Greentown China saw a significant increase of 9.09%, reaching a latest price of 9.000 and a total market capitalization of 22.856 billion [2] - Other companies such as Oceanwide Holdings and R&F Properties also reported substantial gains of 8.65% and 7.55% respectively [2] Group 2 - Shimao Group increased by 5.77%, with a latest price of 0.275 and a market cap of 23.66 billion [2] - Companies like Jianfa International Group, China Resources Land, and China Jinmao rose over 4%, indicating a positive trend in the sector [1][2] - Year-to-date performance shows mixed results, with some companies like Oceanwide Holdings and R&F Properties down by 54.25% and 58.09% respectively [2]

Group 1 - Hong Kong real estate stocks showed strong performance on November 10, with Greentown China rising over 9% [2] - R&F Properties increased by more than 7% [2] - Shimao Group saw an increase of over 5% [2]

世茂集团(00813)发布公告，截至2025年10月31日止10个月，本集团的累计合约销售总额约为人民币 209.19亿元，同比减少26.47%，本集团的累计合约销售总面积约172.1万平方米。截至2025年10月31日 止10个月的平均销售价格为每平方米人民币约1.22万元。 本集团于2025年10月的合约销售额约为人民币17.02亿元，同比减少45.27%，合约销售面积约13.89万平 方米。2025年10月平均销售价格为每平方米人民币约1.22万元。 ...

集团于2025年10月的合约销售额约为人民币17.02亿元，合约销售面积为138,941平方米。2025年10月平 均销售价格为每平方米人民币12,249元。 格隆汇11月7日丨世茂集团(00813.HK)公布，截至2025年10月31日止十个月，集团的累计合约销售总额 约为人民币209.19亿元，集团的累计合约销售总面积为1,721,003平方米。截至2025年10月31日止十个月 的平均销售价格为每平方米人民币12,155元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 世茂集團控股有限公司 主席及總裁 許世壇 （於開曼群島註冊成立之有限公司） （股份代號： 813） 截至2025年10月31日止十個月 未經審核營運數據 世茂集團控股有限公司（「本公司」）董事會（「董事會」）謹此公佈本公司及其 附屬公司（統稱為「本集團」）截至2025年10月31日止十個月若干未經審核營運數 據如下： 上述銷售數據未經審核，乃根據本集團初步內部資料編製，鑒於收集該等銷售資料 過程中存在各種不確定因素，該等銷售數據與本公司按年度或半年度刊發的經審核 或未經審核綜合財務報表中披露的數字可能存在差異，因此上述數據僅供投資者參 考。投資者買賣本公司證券時務須謹慎行事，避免不恰當地倚賴該等資料。如有任 何疑問，投資者應尋求專業人士或財務顧問的專業意見。 代表董事會 香港，2025 年 11 月 7 日 於本公告日期，本公司董事會包括三位執行董事許世壇先生（主席及總裁）、謝琨 先生及趙軍先生；兩位非 ...

Core Viewpoint - The Shimao Tower in Beijing's Chaoyang District was sold at a significant discount, raising questions about the implications of a pharmaceutical company, Yangtze River Pharmaceutical Group, entering the real estate market and the current situation of Shimao Group after multiple asset disposals [1][5]. Group 1: Transaction Details - The Shimao Tower was auctioned for 2.254 billion yuan, which is approximately 70% of its latest assessed value of 3.22 billion yuan [3][4]. - The buyer, Beijing Yangtze River Real Estate Co., Ltd., is a wholly-owned subsidiary of Yangtze River Pharmaceutical Group, which was established in late October 2023 [3][4]. - The building, completed in 2006, has a total area of 70,000 square meters and is located in a prime business district near major transportation and luxury amenities [3][4]. Group 2: Yangtze River Pharmaceutical Group Overview - Yangtze River Pharmaceutical Group, founded in 1971, is a leading player in the domestic pharmaceutical industry, with projected revenues of 73.93 billion yuan in 2024, ranking first among private pharmaceutical companies [4]. - The company has a gross margin of approximately 65% and a net margin of about 18%, both exceeding industry averages [4]. - The group is expanding its footprint in the real estate sector as part of its broader strategy to develop a health management ecosystem, with ongoing projects in key regions [4][5]. Group 3: Shimao Group's Current Situation - Shimao Group, once known for its luxury real estate developments, has been selling assets to recover funds after declaring a default on a $1 billion overseas debt in July 2022 [6][7]. - The company has sold various landmark properties and has been actively restructuring its overseas debt, which amounts to approximately $14.4 billion [7][8]. - In the first half of 2023, Shimao Group reported revenues of 14.827 billion yuan, with a net loss of 8.934 billion yuan, indicating a significant reduction in losses compared to the previous year [8][9].

Core Viewpoint - Yangtze River Pharmaceutical Group's subsidiary acquired the Beijing Shimao Building for 2.254 billion yuan, significantly below its appraised value of 3.22 billion yuan, indicating a strategic investment opportunity in the real estate sector [1] Group 1: Acquisition Details - The property auctioned includes a commercial building with a total construction area of 70,174 square meters located in Chaoyang District, Beijing [1] - The starting price for the auction was set at 2.254 billion yuan, and the final transaction price represented a 30% discount from the appraised value [1] Group 2: Company Background - Beijing Yangtze River Real Estate Co., Ltd. is a wholly-owned subsidiary of Yangtze River (Guangdong Hengqin) Health Investment Co., Ltd., which is fully owned by Yangtze River Pharmaceutical Group [1]

FF301 本月底法定/註冊股本總額： HKD 2,500,000,000 第 1 頁 共 10 頁 v 1.1.1 致：香港交易及結算所有限公司 公司名稱: 世茂集團控股有限公司（於開曼群島註冊成立之有限公司） 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00813 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | HKD | | 0.1 HKD | | 2,500,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | ...

Core Viewpoint - Shimao Group (00813) announced that its subsidiary, Shanghai Shimao Co., Ltd., achieved a revenue of 4.292 billion yuan in the first three quarters of 2025, representing a year-on-year growth of 7.65% [1] Financial Performance - The revenue for the first three quarters of 2025 reached 4.292 billion yuan [1] - This figure indicates a year-on-year increase of 7.65% [1]